A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C.
Interferon treatment reduces the serum level of hepatitis C virus (HCV) and improves inflammatory activity, but relapse is frequently observed. In an attempt to develop a new therapeutic strategy that may reduce relapse and cure the disease, we evaluated the effect of corticosteroid priming on lymphoblastoid interferon alfa in an open randomized clinical trial. The level of HCV RNA increased significantly during corticosteroid priming (from 5.60 [median] to 21.0 x 10(5) Eq/mL; P = .0004) but decreased to the pretreatment level 4 weeks after cessation of corticosteroid (7.0 x 10(5) Eq/mL; P = .07). Sustained normalization of alanine transaminase (ALT) level and virus clearance, confirmed by negative results for HCV RNA using reverse-transcription nested polymerase chain reaction (PCR), were observed over a period of 6 months in 8 of 19 (42.1%) corticosteroid-primed patients, compared with 6 of 19 patients (31.6%) treated with interferon only. A "rebound" of ALT after the withdrawal of corticosteroid was observed in only 2 of 19 patients primed with corticosteroid, but both showed sustained responses. Multivariate analysis for factors predictive of the sustained response indicated that HCV titers measured immediately before interferon therapy and HCV genotype were statistically significant (P = .006 and P = .025, respectively). Our results indicated that corticosteroid priming has a marginal benefit over treatment with interferon alone and that large-scale clinical trials are necessary to determine whether interferon with corticosteroid priming is more effective than interferon alone.
Chayama
K
K
Department of Gastroenterology, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
Tsubota
A
A
Kobayashi
M
M
Hashimoto
M
M
Miyano
Y
Y
Koike
H
H
Kobayashi
M
M
Koida
I
I
Arase
Y
Y
Saitoh
S
S
Murashima
N
N
Ikeda
K
K
Kumada
H
H
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005260:Female; D005838:Genotype; D005938:Glucocorticoids / Q000627:therapeutic use*; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy / Q000628:therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010865:Pilot Projects; D016133:Polymerase Chain Reaction; D011239:Prednisolone / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood
D000998:Antiviral Agents; D005938:Glucocorticoids; D016898:Interferon-alpha; D012367:RNA, Viral; D011239:Prednisolone; D000410:Alanine Transaminase